8-K: Enveric Biosciences Out-Licenses EB-002 to MycoMedica for $62 Million Potential Milestone Payments

Enveric Biosciences has entered into an agreement to out-license its EB-002 drug candidate to MycoMedica Life Sciences, potentially earning up to $62 million in milestone payments and tiered royalties.

Summary

• Enveric Biosciences has signed an out-licensing agreement with MycoMedica Life Sciences for its EB-002 drug candidate and the EVM201 series.
• MycoMedica will receive an exclusive global license to develop and commercialize EB-002 for neuropsychiatric disorders.
• Enveric will receive modest upfront payments, and is eligible for up to $62 million in development and sales milestone payments.
• Enveric will also receive tiered single-digit royalties on future sales of EB-002.
• MycoMedica has the option to buyout milestone and royalty obligations at a predetermined amount.
• MycoMedica can purchase the licensed patents for a nominal amount upon a change of control of Enveric, but this does not relieve them of payment obligations.
• Enveric is prioritizing the development of its EB-003 drug candidate and will use the proceeds from this deal to focus on that program.
• MycoMedica will be responsible for all future preclinical, clinical, and commercial development of EB-002.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a strategic move to monetize an asset while focusing on a lead program. The potential for milestone payments and royalties is a positive sign, although the modest upfront payments and reliance on a third party for EB-002 development temper the overall sentiment.

Positives

• Enveric secures potential revenue through milestone payments and royalties without further development costs for EB-002.
• The agreement allows Enveric to focus resources on its lead drug candidate, EB-003.
• MycoMedica's expertise in neuropsychiatric disorders may accelerate the development and commercialization of EB-002.
• The deal provides a potential long-term revenue stream for Enveric.
• The agreement includes a buyout option for MycoMedica, potentially providing additional revenue for Enveric.

Negatives

• Enveric is giving up control over the development and commercialization of EB-002.
• The upfront payments are described as modest, suggesting they may not be substantial.
• The milestone payments are contingent on MycoMedica achieving certain development and sales targets.
• The royalty payments are tiered single-digit, which may not be a large percentage of sales.

Risks

• MycoMedica may not successfully develop and commercialize EB-002.
• The milestone payments may not be fully realized if development or sales targets are not met.
• The royalty payments may not be substantial if sales of EB-002 are low.
• There is a risk that MycoMedica may not exercise the buyout option.
• Enveric is now reliant on MycoMedica for the success of EB-002.

Future Outlook

Enveric will focus on advancing EB-003 towards clinical trials with an Investigational New Drug application planned for 2025, while MycoMedica will develop and commercialize EB-002.

Management Comments

• Joseph Tucker, Ph.D., CEO of Enveric, stated that the out-licensing of EB-002 allows the company to focus on EB-003 while still realizing potential revenue from EB-002.
• Sanjay Dub M.D., MycoMedica's CEO and CMO, expressed excitement about the agreement and continuing the development of EB-002.

Industry Context

This agreement reflects a trend in the biotech industry where companies out-license assets to focus on core programs, while still generating potential revenue from other assets. It also highlights the growing interest in treatments for neuropsychiatric disorders.

Comparison to Industry Standards

• Out-licensing agreements are common in the biotech industry, allowing companies to monetize assets without bearing the full cost of development.
• Milestone payments and royalties are standard components of such agreements, with the specific terms varying based on the stage of development and market potential of the asset.
• The potential $62 million in milestone payments is a significant amount, but not unusual for a drug candidate in the early stages of development.
• Tiered single-digit royalties are typical for out-licensing agreements, with the specific percentage depending on the market potential and risk associated with the asset.
• Companies like Neurocrine Biosciences and Acadia Pharmaceuticals have similar out-licensing deals for their drug candidates.

Stakeholder Impact

• Shareholders may view the out-licensing agreement positively due to the potential for future revenue.
• Employees may be impacted by the shift in focus to EB-003.
• Patients may benefit from the development of new treatments for neuropsychiatric disorders.
• MycoMedica will become a key partner for Enveric.

Next Steps

• MycoMedica will begin development and commercialization of EB-002.
• Enveric will focus on advancing EB-003 towards clinical trials, with an Investigational New Drug application planned for 2025.

Key Dates

Keywords

out-licensing, EB-002, MycoMedica, neuropsychiatric disorders, milestone payments, royalties, EVM201, EB-003, licensing agreement, biotechnology